| Diabetes Mellitus, Non-Insulin-Dependent

Kerendia vs Welchol

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.
Deep comparison between: Kerendia vs Welchol with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsWelchol has a higher rate of injection site reactions vs Kerendia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Welchol but not Kerendia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Kerendia
Welchol
At A Glance
Oral
Once daily
Mineralocorticoid receptor antagonist
Oral
Daily
Bile acid sequestrant
Indications
  • Chronic Kidney Diseases
  • Diabetes Mellitus, Non-Insulin-Dependent
  • Heart failure
  • Chronic kidney disease stage 5
  • Myocardial Infarction
  • Familial hyperlipidemia
  • Familial hypercholesterolemia - heterozygous
  • Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Chronic Kidney Diseases, Diabetes Mellitus, Non-Insulin-Dependent Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg once daily, adjusted after 4 weeks based on serum potassium levels.
Heart failure Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg or 40 mg once daily based on eGFR at initiation, adjusted after 4 weeks.
Familial hyperlipidemia, Familial hypercholesterolemia - heterozygous 3.75 grams daily; 6 tablets once daily or 3 tablets twice daily with a meal and liquid, or one packet oral suspension once daily with a meal.
Diabetes Mellitus, Non-Insulin-Dependent 3.75 grams daily; 6 tablets once daily or 3 tablets twice daily with a meal and liquid, or one packet oral suspension once daily with a meal.
Contraindications
  • Hypersensitivity to any component of Kerendia
  • Concomitant treatment with strong CYP3A4 inhibitors
  • Adrenal insufficiency
  • Serum TG concentrations >500 mg/dL
  • History of hypertriglyceridemia-induced pancreatitis
  • History of bowel obstruction
Adverse Reactions
Most common (>=10%) hyperkalemia
Serious hyperkalemia requiring hospitalization, renal impairment, acute kidney injury, renal failure
Postmarketing angioedema, rash, urticaria
Most common (>=2%) Constipation, dyspepsia, nausea, asthenia, pharyngitis, myalgia (primary hyperlipidemia); constipation, dyspepsia, nausea, hypertension, back pain (type 2 diabetes)
Serious Hypertriglyceridemia, pancreatitis, gastrointestinal obstruction, vitamin K and fat-soluble vitamin deficiencies
Postmarketing Bowel obstruction, dysphagia, esophageal obstruction, fecal impaction, pancreatitis, hypertriglyceridemia, increased transaminases
Pharmacology
Finerenone is a nonsteroidal, selective mineralocorticoid receptor (MR) antagonist that blocks MR-mediated sodium reabsorption and MR overactivation in epithelial (kidney) and nonepithelial (heart, blood vessels) tissues; it has high potency and selectivity for the MR with no relevant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors.
Colesevelam hydrochloride is a non-absorbed bile acid sequestrant that binds bile acids in the intestine, depletes the bile acid pool, upregulates hepatic cholesterol 7-alpha-hydroxylase, increases LDL receptor expression, and thereby lowers serum LDL-C; the mechanism by which it improves glycemic control in type 2 diabetes is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kerendia
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (9/12) · Qty limit (11/12)
View full coverage details ›
Welchol
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
View full coverage details ›
UnitedHealthcare
Kerendia
  • Covered on 4 commercial plans
  • PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
View full coverage details ›
Welchol
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Humana
Kerendia
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
View full coverage details ›
Welchol
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Bayer US Patient Assistance Foundation - Kerendia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Welchol.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
KerendiaView full Kerendia profile
WelcholView full Welchol profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.